EA200200858A1 - Фармацевтические композиции, содержащие ингибиторы гликогенфосфорилазы - Google Patents

Фармацевтические композиции, содержащие ингибиторы гликогенфосфорилазы

Info

Publication number
EA200200858A1
EA200200858A1 EA200200858A EA200200858A EA200200858A1 EA 200200858 A1 EA200200858 A1 EA 200200858A1 EA 200200858 A EA200200858 A EA 200200858A EA 200200858 A EA200200858 A EA 200200858A EA 200200858 A1 EA200200858 A1 EA 200200858A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phosphorilase
pharmaceutical compositions
compositions containing
containing inhibitors
glycogen
Prior art date
Application number
EA200200858A
Other languages
English (en)
Inventor
Деннис Джей Хувер
Рави Майсор Шэнкер
Дуэйн Томас Фрезен
Дуглас Алан Лоренц
Джеймс Алан Шривер Найтингэйл
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200200858A1 publication Critical patent/EA200200858A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

Настоящее изобретение относится к фармацевтической композиции, содержащей ингибитор гликогенфосфорилазы и, по крайней мере, один повышающий концентрацию полимер, которая может представлять простую физическую смесь ингибитора гликогенфосфорилазы и повышающего концентрацию полимера или дисперсию ингибитора гликогенфосфорилазы и полимера.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200858A 2000-03-16 2001-03-16 Фармацевтические композиции, содержащие ингибиторы гликогенфосфорилазы EA200200858A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16
PCT/IB2001/000394 WO2001068055A1 (en) 2000-03-16 2001-03-16 Pharmaceutical compositions of glycogen phosphorylase inhibitors

Publications (1)

Publication Number Publication Date
EA200200858A1 true EA200200858A1 (ru) 2003-02-27

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200858A EA200200858A1 (ru) 2000-03-16 2001-03-16 Фармацевтические композиции, содержащие ингибиторы гликогенфосфорилазы

Country Status (32)

Country Link
US (1) US20010053778A1 (ru)
EP (1) EP1263414A1 (ru)
JP (1) JP2003526654A (ru)
KR (1) KR20020081445A (ru)
CN (1) CN1418089A (ru)
AP (1) AP2002002621A0 (ru)
AR (1) AR027656A1 (ru)
AU (1) AU2001242669A1 (ru)
BG (1) BG107037A (ru)
BR (1) BR0109189A (ru)
CA (1) CA2403241A1 (ru)
CO (1) CO5280087A1 (ru)
CZ (1) CZ20022955A3 (ru)
EA (1) EA200200858A1 (ru)
EE (1) EE200200530A (ru)
HU (1) HUP0204583A2 (ru)
IL (1) IL151320A0 (ru)
IS (1) IS6508A (ru)
MA (1) MA26882A1 (ru)
MX (1) MXPA02009097A (ru)
NO (1) NO20024386L (ru)
OA (1) OA12232A (ru)
PA (1) PA8513601A1 (ru)
PE (1) PE20011184A1 (ru)
PL (1) PL360780A1 (ru)
SK (1) SK12622002A3 (ru)
SV (1) SV2002000343A (ru)
TN (1) TNSN01040A1 (ru)
TR (1) TR200202184T2 (ru)
WO (1) WO2001068055A1 (ru)
YU (1) YU67202A (ru)
ZA (1) ZA200207290B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1712222A3 (en) * 1999-12-23 2012-06-20 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
OA12625A (en) 2001-06-22 2006-06-12 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug.
DE60233874D1 (de) 2001-06-22 2009-11-12 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
CA2474958A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
WO2003063822A2 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
ATE483708T1 (de) 2004-03-08 2010-10-15 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
US20150202301A1 (en) * 2012-08-24 2015-07-23 Dow Global Technologies Llc Novel esterified cellulose ethers of high molecular weight and homogeneity
LT3725778T (lt) 2012-09-11 2021-12-27 Medivation Prostate Therapeutics Llc Enzalutamido kompozicijos
CN111635353A (zh) * 2013-07-19 2020-09-08 西佳技术公司 非晶形特考韦瑞制备
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
CZ20022955A3 (cs) 2003-09-17
AP2002002621A0 (en) 2002-09-30
MXPA02009097A (es) 2003-03-12
MA26882A1 (fr) 2004-12-20
CA2403241A1 (en) 2001-09-20
SK12622002A3 (sk) 2004-02-03
SV2002000343A (es) 2002-07-03
NO20024386D0 (no) 2002-09-13
NO20024386L (no) 2002-11-13
YU67202A (sh) 2006-01-16
WO2001068055A1 (en) 2001-09-20
CO5280087A1 (es) 2003-05-30
HUP0204583A2 (hu) 2003-04-28
PE20011184A1 (es) 2001-11-15
KR20020081445A (ko) 2002-10-26
PA8513601A1 (es) 2004-08-31
JP2003526654A (ja) 2003-09-09
IL151320A0 (en) 2003-04-10
EP1263414A1 (en) 2002-12-11
EE200200530A (et) 2004-04-15
CN1418089A (zh) 2003-05-14
OA12232A (en) 2006-05-10
ZA200207290B (en) 2003-09-11
BR0109189A (pt) 2003-05-27
AR027656A1 (es) 2003-04-09
PL360780A1 (en) 2004-09-20
AU2001242669A1 (en) 2001-09-24
US20010053778A1 (en) 2001-12-20
BG107037A (bg) 2003-04-30
IS6508A (is) 2002-08-16
TNSN01040A1 (fr) 2005-11-10
TR200202184T2 (tr) 2003-01-21

Similar Documents

Publication Publication Date Title
EA200200858A1 (ru) Фармацевтические композиции, содержащие ингибиторы гликогенфосфорилазы
BR0317822A (pt) Composição fluoroquìmica
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
CY1110602T1 (el) Φαρμακευτικες συνθεσεις υπο μορφη γελης ή διαλυματος με βαση τη διυδροτεστοστερονη, μεθοδοι παρασκευης και χρησεις τους
EA200400980A1 (ru) Ингибиторы асс
ATE346035T1 (de) Inhibitoren von serin proteasen, insbesondere von hepatitis c virus ns3 protease
BR0212968A (pt) Composição farmacêutica, composto, e, método para tratar ou prevenir condições mediadas pelo ccr2, mcp-1 ou pela interação destes
EA200601002A1 (ru) 6-алкенил и 6-фенилалкил замещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
ID26033A (id) Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
BR0113989A (pt) Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
EA200701297A1 (ru) Соединения пиридазинона
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
BR0211390A (pt) Tratamento de infecções da unha com no
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
DK1515702T6 (da) Misbrugssikret indgivelsesform
HUP9900152A2 (hu) Alkoholalapú mikrobaellenes kozmetikai készítmény és alkalmazása
EA200401157A1 (ru) N-аминоацетилпирролидин-2-карбонитрилы и их применение в качестве ингибиторов ddp-iv
PA8548801A1 (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
BR9814698A (pt) Combinação de um inibidor da aldose-redutase com um inibidor do glicogênio-fosforilase
ATE512208T1 (de) Duftstoffkombination enthaltend 3, 7-dymethyl-6- en-nitril (citronellyl nitril) als geranonitril- substitut
ATE507822T1 (de) Stabilisierte zusammensetzungen von faktor-vii- polypeptiden
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
MXPA05001061A (es) Composiciones farmaceuticas, acuosas de 2,6-diisopropilfenol.
BRPI0113162B8 (pt) compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos